Abstract: The present invention provides a triple vital bacteria composition, including: powder of Bifidobacterium longum, powder of Lactobacillus acidophilus, and powder of Streptococcus faecalis. The present invention further provides a method for preparing the above triple vital bacteria composition, as well as the protection agents, the fermenting culture medium and the seed culture medium used therein.

Abstract: The present invention relates to the prevention and treatment of obesity and obesity related metabolic syndrome, particularly to the prevention and treatment of obesity by changing intestinal flora. The characteristics of intestinal bacteria are transformed by administration of a microorganism preparation which improves free fatty acid absorption by the bacteria, and free fatty acid absorption in the gastrointestinal tract is thereby decreased by introduction thereof. The present invention provides a method for preventing and treating obesity and obesity related metabolic syndrome, a pharmaceutical composition and diet supplement for prevention and treatment thereof, and modified probiotic strains usable for such purposes. The present invention provides a weight loss effect and shows that the absorption of fatty acids in the gastrointestinal tract is blocked by improving the characteristics of intestinal bacteria and transplanting them, thereby enabling the treatment of obesity.

Abstract: Compositions and methods useful for reducing or eliminating the presence of pathogens in meat or meat products are disclosed. Administration of one or more lactic acid producing microorganisms to a live animal, to a carcass, to meat, to meat products, or in animal feed results in significant reductions in the amount of pathogens potentially harmful to humans when ingested. Synergistic effects can be achieved with the administration of multiple strains of microorganisms.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: The invention relates to the area of health-beneficial preparations and production methods thereof, in particular to the use of thermally pre-treated Lactobacillus preparations having specific bonding capacity for Streptococcus mutans for caries prophylaxis. The invention further relates to the Lactobacillus preparations and thermal pasteurization.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.

Abstract: Sunflower lecithin or sunflower lecithin with oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or, where they are to be combined with probiotics in a carrier, they can preferably be adsorbed to carriers to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: Sunflower lecithin or sunflower lecithin with oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or, where they are to be combined with probiotics in a carrier, they can preferably be adsorbed to carriers to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Abstract: Compositions and methods useful for reducing or eliminating the presence of pathogens in meat and meat products are disclosed. Administration of one or more lactic acid producing microorganisms to a live animal, to a carcass, to meat, to meat products, or in animal feed results in significant reductions in the amount of pathogens potentially harmful to humans when ingested. Synergistic effects can be achieved with the administration of multiple strains of microorganisms.

Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.

Abstract: The invention described relates to novel strains of lactic acid bacteria and their use in anti-allergy. The composition may be in the form of foodstuffs or in the form of pharmaceutical compositions.

Abstract: The present invention provides an antiallergic agent containing, as an active ingredient, lactic acid bacteria selected from the group consisting of lactic acid bacteria of the species Lactobacillus acidophilus, Lactobacillus fermentum, and combinations thereof. The antiallergic agent is capable of improving allergic diathesis by reducing the IgE level, which is contributive to development of Type I allergy, and is easy to take and highly safe. The present invention also provides use of the antiallergic agent for reducing allergy, and a method for reducing allergy using the antiallergic agent.

Abstract: The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof.

Abstract: The invention relates to the use of at least one strain of lactic acid bacteria and/or bifidobacteria having hydrophobic surface properties, for the preparation of a composition intended for the prevention or the treatment of endotoxin mediated and/or associated disorders and human or pet food compositions prepared thereof.

Abstract: The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.

Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Abstract: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an animal. An alternative treatment method comprises administering a therapeutically effective amount of a lactic acid producing bacterium such as Lactobacillus acidophilus in combination with a lactate utilizing bacterium such as Propionibacterium freudenreichii.

Abstract: A method for converting organic solid waste into humic products and the corresponding apparatus, in which a preliminary aerobic fermentation of the organic solid waste is performed, followed by a second aerobic fermentation of the organic waste in the presence of specific microorganisms in order to provide a basic precursor on which the selective metabolization occurs of specific bacterial strains to provide the humic product.

Abstract: The purified strain of Lactobacillus acidophilus CNCM/I-1492 (L.a. 1492) when administered alone or in combination with another Lactobacillus acidophilus (L.a.) strain and Lactobacillus casei (L.c.) strain, has a beneficial effect on the cholesterol blood level in mammals. It also strenghtens the immune system, facilitates the absorption of nutrients and stimulates the intestinal flora. Such strains also neutralize side effects caused by antibiotics. The invention concerns the specific strain L.a. I-1492, a ferment comprising L.a. I-1492, L.a. and L.c. strains, a dairy product obtained by this ferment and a method of manufacturing the dairy product.

Abstract: The use of sphingomyelinase to increase the levels of skin and mucosal ceramides, as well as dermatological and cosmetic compositions containing same which are suitable for topical application are disclosed.

Abstract: The invention concerns lactic acid bacteria with anxiolytic properties and not inducing sedative effect. Said lactic acid bacteria are useful in particular for preparing foods or medicines.

Abstract: A method of improving sleep in a mammal having a sleep disorder is disclosed. The method includes identifying the mammal having a sleep disorder and then administering Lactobacillus acidophilus CNCM I-2274, Lactobacillus acidophilus CNCM I-2132, Lactobacillus helveticus CNCM I-2275, Streptococcus thermophilus CNCM I-1520, Streptococcus thermophilus CNCM I-2272 or mixtures thereof. The method increases the length of the non rapid eye movement sleep phase and decreases the length of the rapid eye movement sleep phase. The bacteria can be administered in an orally consumable food product or a dietary supplement.

Abstract: Novel bacteria Lactobacillus rhamnosus HN001 and HN 067, Lactobacillus acidophilus HN017, and Bifidobacterium lactis HN019 are claimed. Each strain provides immune enhancing effects when ingested.

Abstract: This invention provides a microbe composition comprising three viable and beneficial lactic acid producing bacteria of new strains: Bifidobacterium longum 6-1 (CCTCC Number M 98003), Lactobacillus acidophilus YIT 2004 (CCTCC Number M 98004) and Sterptococcus faecalis YIT 0027 (CCTCC Number M 98005). This invention also provides the materials to protect the viability of the lactic acid producing bacteria in lyophilized form and the method to prepare the composition. Finally, this invention provides various uses of the composition.

Abstract: The present invention relates to a novel defined medium suitable to cultivate lactic acid bacteria, such as Lactobaccilus or Bifidobacteria. In particular the present invention pertains to the use of said medium for the isolation of bioactive molecules or functional metabolites.

Abstract: The subject invention provides a novel process and bioreactor for enhancing the bioleaching of metals from sulfide mineral concentrations.

Abstract: The present invention is directed towards isolated lactobacillus biosurfactants and the process for producing same. The present invention is also directed to methods for preventing urogenital infection in mammals using the isolated lactobacillus biosurfactant. The present invention is further directed to methods of inhibiting microbial biofilm formation using the isolated lactobacillus biosurfactant to prevent the formation of bacterial biofilms, and to displace adherent biofilm-forming bacteria from surfaces.

Abstract: Bacterial strains of genus Bacillus closely phenotypically related to genus Lactobacillus. The strains are moderately thermophilic, have amylolytic properties and/or are capable of producing L(+) lactate, and are useful for producing metabolites such as L(+) lactate.

Abstract: Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is described herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus acidophilus.

Abstract: This invention relates to lactobacillus compositions and methods of employing said compositions for treating or preventing urinary tract infections. More particularly, this invention relates to the ability of certain strains of lactobacilli to adhere to uroepithelial or vaginal epithelial cells and to exhibit inhibitory activity against the growth of pathogenic bacteria.

Abstract: This invention relates to Lactobacillus, skim milk, Lactobacillus Growth Factor (LGF) and Lactobacillus compositions and methods of employing the compositions for preventing urogenital infections. More particularly, this invention relates to the ability of strains of hydrophobic or hydrophilic Lactobacillus to adhere to biomaterials, and intestinal, vaginal and uroepithelial cells, to resist the action of certain antimicrobial agents and to dominate the urogenital flora.

Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.

Abstract: Lactobacillus johnsonii strain CNCM I-1225 adheres to Caco-2 cells and inhibits adhesion thereto by enterovirulent and enteroinvasive pathogens.

Abstract: Stomach ulcers are treated by administering orally to a human in need thereof an anti-Helicobacter pylori effective amount of a composition containing, in combination with an ingestible support, a culture of Lactobacillus johnsonii strain CNCM I-1225 or a supernatant phase isolated from a culture of Lactobacillus johnsonii strain CNCM I-1225.

Abstract: Lactic acid bacteria of the genus Lactobacillus which do not exhibit deconjugation of bile acids and inhibition of nutrient absorption, and exhibit lowering of cholesterol in blood and liver. There are two specific Lactobacillus strains which have been disclosed that exhibit these characteristic properties. The two strains are Lactobacillus acidophilus FERM-P-14204 and Lactobacillus acidophilus FERM-P-14205.

Abstract: A vaginal suppository or other type of vaginal pessary such as cream, foam or ointment, which contains as its active ingredients at least one pharmaceutically acceptable, topically safe antimicrobial agent, such as an agent selected from the group of benzalkonium chloride, cetylpyridinium chloride, chlorhexidine gluconate and povidone iodine, imidiazolidinyl urea and diazolidinyl urea and a viable colony of micro-encapsulated lactobacilli bacteria. The viable lactobacilli are included in the suppository in micro encapsulated form, which protects the bacteria during storage of the suppository from the action of the bacteriocidal agent. When exposed to the vaginal milieu the micro encapsulation breaks down sufficiently to release the lactobacili bacteria. The lactobacilli bacteria serve to maintain or re-establish a healthy lactobacilli based flora on the vaginal wall, and excrete hydrogen peroxide and other bactericidins which suppress abnormal flora conditions that promote infections.

Abstract: A novel process for producing lactic acid using the rumen contents collected from slaughtered cattle or sheep is disclosed. The rumen contents are initially incubated for a period of time and under sufficiently low pH conditions effective to kill and/or inactivate non-lactic acid producing bacteria therein. Prior to or following this inactivation, the rumen contents are combined with a supplemental culture medium to form a fermentation broth and provide additional sources of carbohydrate and organic N for enhanced growth of lactic acid bacteria. In the second stage of the process, the fermentation broth is fermented under conditions promoting growth of the lactic acid bacteria to increase their cell mass to high densities. Optimal growth is attained by adjusting the pH of the fermentation broth to between about 6.6 to 7.2 and then incubating under anaerobic conditions for a sufficient time to lower its pH to between about 4.7 and 5.2.

Abstract: Novel plasmids comprising genes which code for the alcohol dehydrogenase and pyruvate decarboxylase are described. Also described are recombinant hosts which have been transformed with genes coding for alcohol dehydrogenase and pyruvate. By virtue of their transformation with these genes, the recombinant hosts are capable of producing significant amounts of ethanol as a fermentation product. Also disclosed are methods for increasing the growth of recombinant hosts and methods for reducing the accumulation of undesirable metabolic products in the growth medium of these hosts. Also disclosed are recombinant host capable of producing significant amounts of ethanol as a fermentation product of oligosaccharides and plasmids comprising genes encoding polysaccharases, in addition to the genes described above which code for the alcohol dehydrogenase and pyruvate decarboxylase. Further, methods are described for producing ethanol from oligomeric feedstock using the recombinant hosts described above.

Abstract: A method is provided for reducing the quantity of endotoxin circulating in the blood plasma of a living subject affected by an endotoxin-mediated clinical state. The method employs a formulated preparation comprising at least one persistent, acid-resistant, and colonizing Lactobacillus species in combination with a biocompatible carrier. The user then introduces the formulated preparation to the gastrointestinal tract of the subject on one or on multiple occasions.

Abstract: Methods for maintaining and for preparing at a livestock feedlot a concentrated suspension of bacteria at a known, accurate concentration and for storing the prepared suspension for prolonged periods at the feedlot in a ready-to-use condition without significant loss of viability, allowing feedlot operators to conveniently administer such bacterial supplements to large numbers of livestock as a probiotic on a regular basis in accurate dosages. The method of administering the bacterial supplements includes, an insulated liquid-holding vessel cooled by refrigeration appliance, and mixing and recirculating appliances to ensure temperature and concentration homogeneity of the bacterial suspension. The vessel and contents are gravimetrically monitored to ensure accuracy of bacterial concentration.

Abstract: A deep-cleaning, topical surfactant in liquid form containing; polyethylene glycol alkylphenol ether containing 9 glycol units, Trypsin; Chymotrypsin; Pepsin; Lactobacillus Acidophilus; Ethanol; Hydrogen Peroxide, Acetic acid; and Deionized water.

Abstract: 2-Oxo-4-phenylbutyric acid is treated with a microorganism, which has been optionally treated, capable of asymmetrically reducing 2-oxo-4-phenylbutyric acid into either (R)-2-hydroxy-4-phenylbutyric acid or (S)-2-hydroxy-4-phenylbutyric acid, and the (R)-2-hydroxy-4-phenylbutyric acid or (S)-2-hydroxy-4-phenylbutyric acid thus produced is recovered to thereby give optically active 2-hydroxy-4-phenylbutyric acid.The optically active 2-hydroxy-4-phenylbutyric acid is an important intermediate in the synthesis of various drugs such as a remedy for hypertension.

Abstract: A new strain Lactobacillus sp. KPB-176, which does not possess strict selectivity for specific media and which involves no reduction in the productivity of polysaccharides even during subculture, was isolated from kefir grains. When this new strain is cultured on a medium containing milk whey and casamino acid or when on a medium containing carbohydrate and yeast extract, capsular polysaccharides are produced in high yields.

Abstract: New strains of L. acidophilus capable of adhering to the tissue cells of various species of animals and having resistance to both erythromycin and streptomycin are described. The strains may be used in a suitable carrier as a dietary supplement for providing a source of the bacteria in an animal.

Abstract: A biologically pure culture of a strain of bacteria of the species Lactobacillus acidophilus, the bacteria being characterized in that an average of at least 50 of the bacteria can adhere to one human small intestinal mucosal cell after a five minute incubation of the bacteria with the cell.

Abstract: New strains of Lactobacillus capable of adhering to the gut epithelial cells of various species of animals and useful as dietary supplements.

Abstract: Dried viable bacteria are admixed in a particulate carrier composed primarily of an inorganic salt of low moisture absorbing capacity together with a minor proportion of a silica gel absorbent. The inorganic salts may be sodium or calcium carbonates, bicarbonates, sulfates, or phosphates. The admixtures are storable without refrigeration.

Abstract: New strains of Lactobacillus acidophilus capable of adhering to the tissue cells of various species of animals are described. At least one new strain exhibits calcium-independent attachment which is enhanced by the presence of calcium. The strains may be used in a suitable carrier as a dietary supplement for providing a source of the strain of bacteria in an animal.

Abstract: A method and apparatus for preparing at a livestock feedlot a concentrated suspension of anaerobic bacteria at a known, accurate concentration and for storing the prepared suspension for prolonged periods at the feedlot in a ready-to-use condition without significant loss of viability, allowing feedlot operators to conveniently administer such bacterial supplements to large numbers of livestock as a probiotic on a regular basis in accurate dosages. The apparatus comprises an insulated liquid-holding vessel cooled by a refrigeration means, and mixing and recirculation means to ensure temperature and concentration homogeneity of the bacterial suspension. The vessel and contents are gravimetrically monitored to ensure accuracy of bacterial concentration.